We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.76 | -1.34% | 129.33 | 131.74 | 129.16 | 131.74 | 2,618,250 | 20:20:54 |
From May 2019 to May 2024
By Colin Kellaher
Merck & Co. on Wednesday said its cancer drug Keytruda met its primary endpoints in a Phase 3 study in esophageal cancer.
The Kenilworth, N.J., drug maker said Keytruda in combination with chemotherapy showed a statistically significant and clinically meaningful improvement in overall survival and progression-free survival versus chemotherapy alone as the first-line treatment of patients with locally advanced or metastatic esophageal cancer.
Merck said the study also met the key secondary endpoint of objective response rate, adding that Keytruda's safety profile was consistent with that observed in previously studies.
Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, has been approved in several indications in numerous cancers.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 19, 2020 07:23 ET (11:23 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
